Core Viewpoint - Vivani Medical, Inc. is preparing to present its innovative drug implant technology at the H.C. Wainwright 27th Annual Global Investment Conference, focusing on improving medication adherence and patient outcomes in chronic disease management [1][3]. Company Overview - Vivani Medical, Inc. is a clinical-stage biopharmaceutical company specializing in miniature, ultra long-acting drug implants [1][3]. - The company utilizes its proprietary NanoPortal™ technology to develop biopharmaceutical implants that deliver drug molecules steadily over extended periods [3]. - Medication non-adherence affects approximately 50% of patients, highlighting the need for innovative solutions [3]. Product Pipeline - The priority product candidate is NPM-139, a miniature, six-month, subdermal GLP-1 (semaglutide) implant aimed at chronic weight management in obese or overweight individuals [3]. - NPM-139 has the potential for once-yearly dosing, which could significantly enhance patient compliance [3]. - Other products in development include NPM-115 (exenatide implant) for chronic weight management and NPM-119 (exenatide implant) for type-2 diabetes treatment [3]. Upcoming Presentation Details - CEO Adam Mendelsohn will present on September 10, 2025, at the Lotte New York Palace Hotel, focusing on the company's innovative drug implant technology [1]. - The presentation is part of the H.C. Wainwright 27th Annual Global Investment Conference, which runs from September 8-10, 2025 [1].

Core Viewpoint - Vivani Medical, Inc. is advancing its innovative miniature drug implants aimed at improving patient adherence in chronic disease treatment, particularly in the GLP-1 drug class [1][4][5] Company Overview - Vivani Medical, Inc. is a clinical-stage biopharmaceutical company focused on developing ultra long-acting drug implants using its proprietary NanoPortal™ technology [1][4] - The company's lead programs include NPM-115 (exenatide implant) for weight management and NPM-139 (semaglutide implant) for chronic weight management, both designed for infrequent administration [4] Upcoming Events - CEO Adam Mendelsohn will present at the AAPS workshop on May 14, 2025, discussing advances in drug delivery and patient adherence [2][3] - The presentation will focus on the company's lead program, NPM-115, with results from the LIBERATE-1™ study expected this year [2] Industry Context - Medication non-adherence affects approximately 50% of patients, contributing to over $500 billion in avoidable healthcare costs and 125,000 preventable deaths annually in the U.S. [5] - The current GLP-1 landscape includes over 50 new molecular entities in clinical development, highlighting the competitive environment in which Vivani operates [5]